{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-000208","form_type":"8-K","ticker":"VERU","cik":"0000863894","company_name":"VERU INC.","filed_at":"2025-01-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.546700+00:00","generated_at":"2026-05-28T16:54:25.808870+00:00","sec_items":["1.01","1.02","2.01","2.04","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Veru Inc. sells FC2 female condom business for $18M, netting ~$12.5M after change-of-control payment","bullets":["Sold FC2 female condom business to Clear Future, Inc., for $18M cash, subject to working capital adjustment.","Net proceeds to Veru approximately $12.5M after $4.2M change-of-control payment to SWK Funding LLC.","Royalty Agreement with SWK terminated upon payment; related $9.9M liability extinguished.","Headcount reduced by ~90% (from 210 to 22) as Veru focuses on biopharmaceutical pipeline.","Topline results from Phase 2b enobosarm weight loss trial expected in January 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-000208","json":"https://secwatch.observer/filing/0001437749-25-000208.json","markdown":"https://secwatch.observer/filing/0001437749-25-000208.md","text":"https://secwatch.observer/filing/0001437749-25-000208.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/863894/000143774925000208/0001437749-25-000208-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/863894/000143774925000208/veru20241220_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-28T16:54:25.808870+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f2da7c41a4b643710d9a541d6e85ca62292afe0d","claim":"VERU INC. completed a disposition involving Clear Future, Inc. for $18.0 million in cash, subject to customary working capital adjustment (closed 2024-12-30).","evidence_excerpt":"relating to the FC2 business that are specified in the Purchase Agreement. The transaction closed on December 30, 2024. The purchase price for the FC2 Business Sale is $18.0 million in cash, subject to adjustment as set forth in the Purchase Agreement. The adjustments to the purchase price in the Purchase Agreement include a customary working capital","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/863894/000143774925000208/0001437749-25-000208-index.htm","confidence":0.99,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Clear Future, Inc."},{"label":"Consideration","value":"$18.0 million in cash, subject to customary working capital adjustment"},{"label":"Closing","value":"2024-12-30"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}